Status:
UNKNOWN
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Lead Sponsor:
Fundación Teófilo Hernando, Spain
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully. ...
Detailed Description
One decade ago, it was thought that cessation of Tyrosine Kinase Inhibitor (TKI) treatment in chronic myeloid leukemia in chronic phase (CML-CP) patients could be ineluctably followed by relapse, even...
Eligibility Criteria
Inclusion
- Male or female patients ≥ 18 years of age.
- ECOG performance status of 0, 1, or 2.
- Patient with diagnosis of BCR-ABL positive CML-CP.
- Patient has received a minimum of 4 years of imatinib treatment, as unique TKI therapy.
- Patient has achieved MR4 during at least 12 months with imatinib treatment, and determined by PCR lab assessment at screening.
- Adequate end organ function.
- Patients must have the following electrolyte values ≥ LLN limits or corrected to within normal limits with supplements prior to the first dose of study medication: Potassium, Magnesium, Total calcium (corrected for serum albumin).
- Patients must have normal marrow function
- Patients with preexisting, well-controlled, diabetes are not excluded.
- Have normal QTcF interval on screening ECG evaluation, defined as QTcF of ≤ 450 ms in males or ≤ 470 ms in females.
- Have a negative pregnancy test documented prior to enrollment
- Be willing and able to comply with scheduled visits and study procedures.
- Written informed consent obtained prior to any screening procedures.
Exclusion
- Prior AP, BC or autologous or allogenic transplant.
- Patients with known atypical transcript.
- CML treatment resistant mutation(s).
- Are taking medications with a known risk of torsades de pointes (Appendix A)
- Patient ever attempted to permanently discontinue imatinib or ponatinib treatment.
- Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks.
- Have clinically significant, uncontrolled, or active cardiovascular disease.
- Have uncontrolled hypertension (diastolic blood pressure \> 90 mmHg; systolic \> 150 mmHg).
- Have a history of alcohol abuse.
- History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis.
- Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug.
- Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer.
- Have a history of another malignancy; the exception is if patients have been disease-free for at least 5 years.
- Have undergone surgery within 14 days prior to first dose of ponatinib.
- Treatment with other investigational within 4 weeks of Day 1.
- Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers.
- Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers.
- Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval.
- Have an ongoing or active infection.
- Have a known history of human immunodeficiency virus infection.
- Have hypersensitivity to the ponatinib active substance or to any of its inactive ingredients.
- Pregnant or nursing (lactating) women.
Key Trial Info
Start Date :
April 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04043676
Start Date
April 30 2019
End Date
April 30 2023
Last Update
August 2 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Trials i Pujol
Badalona, Barcelona, Spain, 08916
2
Hospital Vall D'Hebron
Barcelona, Spain, 08035
3
Hospital Universitario de Gran Canarias Dr. Negrin
Las Palmas de Gran Canaria, Spain, 35010
4
Hospital Unversitario de la Princesa
Madrid, Spain, 28006